VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
IONS
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
IONSIonis Pharmaceuticals, Inc.
$86.33$14.3B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksIONSCash Flow

Ionis Pharmaceuticals, Inc. (IONS) Cash Flow Statement

30Y historyFree accessUpdated daily

Free cash flow remains significantly pressured, recording a -$814.6M outflow in 2026Q1, largely driven by a $730.1M negative swing in working capital.

IONS Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Cash from Operations-910.63M-268.58M-500.95M-307.51M-274.37M30.8M35.89M345.72M602.89M174.15M-112.11M21.13M6.29M63.49M1.88M-114.8M-63.59M-108.44M212.03M36.09M-53.23M-61.74M-101.75M-95.47M-94.38M-6.16M-23.19M-48.4M-34.7M-20.6M-21.2M
Operating CF Margin %--28.45%-71.04%-39.04%-46.71%3.8%4.92%30.8%100.54%33.87%-30.07%7.45%2.93%43.11%1.84%-115.86%-58.63%-89.18%197.81%61.86%-358.2%-153.84%-238.72%-190.99%-117.71%-11.56%-62.24%-142.77%-88.52%-63%-93.39%
Operating CF Growth %-232.46%46.38%-62.9%-12.08%-990.84%-14.19%-89.62%-42.66%246.19%255.34%-630.67%236.12%-90.1%3284.49%101.63%-80.52%41.36%-151.14%487.44%167.81%13.79%39.32%-6.57%-1.16%-1432.66%73.44%52.09%-39.48%-68.45%2.83%-40.4%
Net Income-326.58M-381.39M-453.9M-366.29M-269.72M-28.6M-486.77M303.26M214.99M-17.3M-86.56M-88.28M-38.98M-60.64M-65.48M-84.8M-61.25M150.67M-11.96M-10.99M-45.9M-72.4M-142.5M-95M-72.24M-73.83M-53.48M-59.2M-43M-31.1M-26.5M
Depreciation & Amortization31.43M22.69M19.65M22.5M22.11M19.56M17.16M15.99M12.53M8.35M9.03M10.24M9.4M9.78M10.76M11.78M9.18M11.33M6.82M6.76M7.22M9.69M12.17M12.25M10.3M6.97M5.54M5.2M4.3M3.2M2.6M
Stock-Based Compensation104.11M0130.2M105.81M100.26M120.68M230.12M146.57M131.31M85.97M72.11M59.31M31.38M11.42M8.57M9.85M12.16M13.38M15.06M9.91M5.75M-544K913K0-3M4.57M00000
Deferred Taxes0000025.31M313.27M-7.1M-290.52M14.07M10.74M-12.47M-12.84M-5.91M-9.11M13.84M16.25M5.25M-26.26M-37.21M-31.03M544K-913K03M-4.57M00000
Other Non-Cash Items-54.49M141.32M12.49M7.73M-134.59M7.67M35.66M55.69M35.17M39.5M34.1M31.75M12.11M22.83M6.93M1.92M1.51M-184.96M17.51M14.02M8.16M9.9M52.8M11.53M-14.38M35.53M25.67M15.5M11.4M400K-100K
Working Capital Changes-665.09M-51.22M-209.39M-77.26M7.57M-113.82M-73.56M-168.71M499.41M43.56M-151.53M20.57M5.21M86.03M50.21M-67.39M-41.44M-104.12M210.86M53.6M2.59M-8.93M-24.22M-24.26M-18.06M25.18M-908K-9.9M-7.4M6.9M2.8M
Change in Receivables-101.56M26.13M5.59M-72.06M36.36M5.05M-22M-44.18M514K15.72M-89.36M-14.12M9.77M-4.98M3.42M2.95M4.71M-16.84M2.91M1.18M1.9M0000000000
Change in Inventory254K-13.67M-5.07M-6.39M2.77M-2.84M-1.26M-5.41M1.4M-2.49M-590K-609K1.74M-1.91M-1.98M-1.66M284K-17K-1.32M-1.96M90K1.77M-9.7M-2.9M-11.09M000000
Change in Payables36.63M-15.36M15.99M8.12M1.09M-6M-2.75M-16.34M-655K1.78M-10.68M9.21M4.82M66K1.29M875K1.32M-3.65M962K-794K1.21M-4.87M-1.8M0-2.15M3.8M00000
Cash from Investing88.58M-277.78M-134.03M-214.13M-262.64M194.91M274.48M-41.27M-929.56M-358.29M56.6M-60.05M-82.85M-255.73M18M110.9M23.69M-212.29M-234.25M-55.64M-32.61M540K83.73M-15.12M-60.37M-143.49M-95.38M-7.9M9.1M-15.2M-11.3M
Capital Expenditures-61.99M-51.44M-45.28M-23.8M-20.1M-17.9M-41.05M-36.28M-17.65M-37.86M-11.53M-11.75M-11.1M-5.36M-5.17M-11M-17.56M-16.29M-17.07M-5.01M-2.56M-422K-3.53M-7.55M-36.83M-9.29M-1.65M-4.8M-4.4M-3.5M-900K
CapEx % of Revenue5.86%5.45%6.42%3.02%3.42%2.21%5.63%3.23%2.94%7.36%3.09%4.14%5.18%3.64%5.07%11.1%16.18%13.4%15.92%8.59%17.2%1.05%8.27%15.11%45.94%17.43%4.43%14.16%11.22%10.7%3.96%
Acquisitions00022K254.08M5.95M5.93M5.38M4.04M2.51M4.47M25.53M22.95M3.81M-3M3.67M6.01M2.88M3.4M-80.4M1.51M14.02M000000000
Investments-------------------------------
Other Investing-5.11M-5.64M-5.06M-4.21M0-5.95M-5.93M-5.38M-4.04M-323.53M63.71M-52.36M-75.33M-3.81M3M-3.67M-11.91M-2.88M-3.4M-83.12M-1.51M832K-16.41M-11.6M-19.05M-36.4M-23.78M-16.5M-4M-3.5M-800K
Cash from Financing730.9M675.84M478.06M644.08M-55.3M245.93M-596.61M100.02M475.87M229.09M11.39M24.73M59.59M227.72M39.13M-672K4.7M202M107.58M43.65M149.46M37.6M12.15M41.85M129.59M237.04M122.88M63.9M15.1M36.7M23M
Debt Issued (Net)483.23M483.24M-44.67M86.9M-50.69M313.57M097M0-23.98M-3.07M-558K35.05M-8.53M29.66M-4.24M340K3.57M4.81M22.3M-7.85M-11.57M8.1M40.15M129.59M26.58M4.64M-400K11.2M36.7M23.1M
Equity Issued (Net)247.66M192.6M522.73M49.44M6.37M85.71M-103.96M85.27M475.87M255.11M13.42M24.89M23.07M003.57M4.36M13.16M62.68M11.35M86.36M49.17M4.05M1.7M8.89M210.46M064.3M3.9M00
Dividends Paid0000000000000000000000000000000
Share Repurchases000000-90.55M-34.39M00000000000000000000000
Other Financing000507.74M-10.98M-153.34M-492.65M-82.24M0-2.04M1.04M396K1.46M236.25M9.47M00185.28M40.1M10M70.95M000-8.89M0118.24M000-100K
Net Change in Cash-90.81M130.18M-157.19M122.79M-592.72M471.53M-285.62M404.47M149.19M44.95M-44.11M-14.2M-16.98M35.49M59.01M-4.58M-35.2M-118.73M85.37M24.1M63.63M-23.6M-5.87M-68.74M-25.16M87.4M4.32M7.7M15.1M36.7M23M
Free Cash Flow-971.26M-320.03M-546.23M-335.52M-294.47M12.9M-5.16M309.44M585.24M136.29M-123.63M9.38M-4.82M58.13M-3.29M-125.8M-81.15M-124.73M194.96M31.08M-55.78M-62.16M-105.28M-103.03M-131.22M-15.45M-24.84M-53.2M-39.1M-24.1M-22.1M
FCF Margin %-91.81%-33.9%-77.46%-42.6%-50.13%1.59%-0.71%27.56%97.59%26.51%-33.17%3.31%-2.25%39.47%-3.23%-126.96%-74.81%-102.58%181.89%53.28%-375.4%-154.89%-246.99%-206.1%-163.65%-28.99%-66.66%-156.93%-99.74%-73.7%-97.36%
FCF Growth %-70.64%41.41%-62.8%-13.94%-2383.06%350.16%-101.67%-47.13%329.4%210.24%-1418.47%294.58%-108.29%1864.75%97.38%-55.02%34.94%-163.98%527.22%155.73%10.27%40.95%-2.18%21.48%-749.56%37.81%53.32%-36.06%-62.24%-9.05%-36.42%
FCF per Share-5.89-2.00-3.65-2.34-2.080.09-0.042.174.371.08-1.020.08-0.040.53-0.03-1.26-0.82-1.272.060.37-0.75-0.99-1.86-1.86-2.41-0.35-0.67-1.85-1.45-0.91-0.87
FCF Conversion (FCF/Net Income)2.97x0.70x1.10x0.84x1.02x-1.08x-0.08x1.24x2.20x503.32x1.86x-0.24x-0.16x-1.05x-0.03x1.35x1.04x-0.70x-11.67x-3.28x1.16x0.85x0.71x1.01x1.31x0.08x0.43x0.82x0.81x0.66x0.80x
Interest Paid5.31M006.51M2.9M4.78M6.25M9.87M000006M04.8M4.89M4.88M0000000000000
Taxes Paid371K0048.33M5.01M38K25.86M9.04M000002K02K7.27M13.21M0000000000000

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Commercialization execution and dilution

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Earnings Quality Obscured by Volatility

As reported in recent financial filings, the relationship between net income and operating cash flow remains highly erratic, with the 2026Q1 period showing an OCF/NI ratio of 8.57, suggesting that non-cash items and working capital swings significantly distort the underlying quality of reported earnings.

The extreme variance in the OCF/NI ratio indicates that net income is a poor proxy for the company's actual cash-generating capacity. Investors should monitor whether this divergence is a temporary byproduct of milestone-based revenue recognition or a structural issue inherent in the transition to a commercial-stage entity.

Free Cash Flow Remains Deeply Negative

Based on the provided cash flow data, Ionis recorded a free cash flow of -$814.6M in 2026Q1, reflecting a persistent and widening cash burn that highlights the significant capital intensity required to support the company's current R&D and commercialization efforts as it pivots away from licensing.

The trajectory of free cash flow suggests that the company is currently in a high-expenditure phase that is not yet offset by commercial product sales. This trend warrants further investigation into the sustainability of the current burn rate without additional non-dilutive financing or milestone payments.

Working Capital Swings Impair Liquidity

According to the quarterly cash flow statements, Ionis experienced a substantial working capital outflow of $730.1M in 2026Q1, which appears to be the primary driver of the quarter's significant cash depletion and underscores the volatility inherent in the company's current operational and revenue cycle.

Such large fluctuations in working capital suggest that the timing of milestone payments and the buildup of commercial inventory are creating significant liquidity pressure. Analysts should interpret these swings as a potential indicator of operational friction as the company scales its internal commercial infrastructure.

Capital Intensity Reflects Infrastructure Build

As indicated by the historical data, Ionis has maintained a relatively consistent capital expenditure profile, with CapEx/Revenue ratios reaching as high as 11.3% in 2024Q4, signaling that the company is actively investing in the physical and technical assets necessary to support its independent commercialization strategy.

While these expenditures are necessary for the transition to a self-commercializing pharma company, they represent a permanent increase in the cost base. The market should monitor whether these investments yield the expected operating leverage or if they will continue to weigh on free cash flow margins.

IONS — Frequently Asked Questions

Quick answers to the most common questions about buying IONS stock.

How much cash does Ionis Pharmaceuticals, Inc. (IONS) generate from operations?

Ionis Pharmaceuticals, Inc. (IONS) generated $-268.6M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Ionis Pharmaceuticals, Inc.'s free cash flow?

Ionis Pharmaceuticals, Inc. (IONS) reported negative free cash flow of $320.0M in 2025, indicating capital requirements exceeded cash from operations.

What is Ionis Pharmaceuticals, Inc.'s capital expenditure (CapEx)?

Ionis Pharmaceuticals, Inc. (IONS) spent $51.4M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.